Breaking News

Monday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Agile Therapeutics price target lowered to $3.50 from $7 at H.C. Wainwright » 06:16
09/13/21
09/13
06:16
09/13/21
06:16
AGRX

Agile Therapeutics

$1.17 /

-0.08 (-6.43%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Oren Livnat lowered the firm's price target on Agile Therapeutics to $3.50 from $7 and keeps a Buy rating on the shares. The analyst updated Twirla projections based on prescription trends which have trended below his projections.

ShowHide Related Items >><<
AGRX Agile Therapeutics
$1.17 /

-0.08 (-6.43%)

AGRX Agile Therapeutics
$1.17 /

-0.08 (-6.43%)

04/06/21 RBC Capital
Agile Therapeutics transferred with an Outperform at RBC Capital
12/08/20 H.C. Wainwright
Agile Therapeutics price target raised to $7 from $6 at H.C. Wainwright
09/22/20 H.C. Wainwright
H.C. Wainwright says Agile coverage, access for Twirla launch underappreciated
AGRX Agile Therapeutics
$1.17 /

-0.08 (-6.43%)

AGRX Agile Therapeutics
$1.17 /

-0.08 (-6.43%)

Over a week ago
Conference/Events
Agile Therapeutics management to meet virtually with Oppenheimer » 05:55
08/25/21
08/25
05:55
08/25/21
05:55
AGRX

Agile Therapeutics

$1.06 /

+0.055 (+5.50%)

Virtual Meetings to be…

Virtual Meetings to be held August 24-25 hosted by Oppenheimer.

ShowHide Related Items >><<
AGRX Agile Therapeutics
$1.06 /

+0.055 (+5.50%)

AGRX Agile Therapeutics
$1.06 /

+0.055 (+5.50%)

04/06/21 RBC Capital
Agile Therapeutics transferred with an Outperform at RBC Capital
12/08/20 H.C. Wainwright
Agile Therapeutics price target raised to $7 from $6 at H.C. Wainwright
09/22/20 H.C. Wainwright
H.C. Wainwright says Agile coverage, access for Twirla launch underappreciated
AGRX Agile Therapeutics
$1.06 /

+0.055 (+5.50%)

AGRX Agile Therapeutics
$1.06 /

+0.055 (+5.50%)

Conference/Events
Agile Therapeutics management to meet virtually with Oppenheimer » 04:55
08/24/21
08/24
04:55
08/24/21
04:55
AGRX

Agile Therapeutics

$1.00 /

-0.01 (-0.99%)

Virtual Meetings to be…

Virtual Meetings to be held August 24-25 hosted by Oppenheimer.

ShowHide Related Items >><<
AGRX Agile Therapeutics
$1.00 /

-0.01 (-0.99%)

AGRX Agile Therapeutics
$1.00 /

-0.01 (-0.99%)

04/06/21 RBC Capital
Agile Therapeutics transferred with an Outperform at RBC Capital
12/08/20 H.C. Wainwright
Agile Therapeutics price target raised to $7 from $6 at H.C. Wainwright
09/22/20 H.C. Wainwright
H.C. Wainwright says Agile coverage, access for Twirla launch underappreciated
AGRX Agile Therapeutics
$1.00 /

-0.01 (-0.99%)

AGRX Agile Therapeutics
$1.00 /

-0.01 (-0.99%)

Conference/Events
Agile Therapeutics management to meet virtually with Oppenheimer » 10:05
08/23/21
08/23
10:05
08/23/21
10:05
AGRX

Agile Therapeutics

$1.00 /

-0.01 (-0.99%)

Virtual Meetings to be…

Virtual Meetings to be held August 24-25 hosted by Oppenheimer.

ShowHide Related Items >><<
AGRX Agile Therapeutics
$1.00 /

-0.01 (-0.99%)

AGRX Agile Therapeutics
$1.00 /

-0.01 (-0.99%)

04/06/21 RBC Capital
Agile Therapeutics transferred with an Outperform at RBC Capital
12/08/20 H.C. Wainwright
Agile Therapeutics price target raised to $7 from $6 at H.C. Wainwright
09/22/20 H.C. Wainwright
H.C. Wainwright says Agile coverage, access for Twirla launch underappreciated
AGRX Agile Therapeutics
$1.00 /

-0.01 (-0.99%)

AGRX Agile Therapeutics
$1.00 /

-0.01 (-0.99%)

Hot Stocks
Agile Therapeutics partners with Pandia Health to increase access to Twirla » 07:32
08/20/21
08/20
07:32
08/20/21
07:32
AGRX

Agile Therapeutics

/

+

Agile Therapeutics…

Agile Therapeutics announced a partnership with Pandia Health which will establish the first telehealth relationship for Agile and offer an additional point of access to Twirla transdermal system in a fast-growing channel. Pandia Health offers convenient prescription fulfillment for women with active birth control prescriptions, as well as access to expert birth control doctors who can provide prescriptions through asynchronous online visits. The Company and Pandia plan to phase in the availability of Twirla in the second half of 2021.

ShowHide Related Items >><<
AGRX Agile Therapeutics
/

+

AGRX Agile Therapeutics
/

+

04/06/21 RBC Capital
Agile Therapeutics transferred with an Outperform at RBC Capital
12/08/20 H.C. Wainwright
Agile Therapeutics price target raised to $7 from $6 at H.C. Wainwright
09/22/20 H.C. Wainwright
H.C. Wainwright says Agile coverage, access for Twirla launch underappreciated
AGRX Agile Therapeutics
/

+

AGRX Agile Therapeutics
/

+

Over a month ago
Earnings
Agile Therapeutics reports Q2 EPS (20c), consensus (21c) » 16:12
07/26/21
07/26
16:12
07/26/21
16:12
AGRX

Agile Therapeutics

$1.12 /

-0.04 (-3.46%)

Reports Q2 revenue…

Reports Q2 revenue $1.19M, consensus $1.95M. As of June 30, Agile had $31.1M of cash, cash equivalents and marketable securities, compared to $54.5M as of December 31, 2020. "The theme of Agile's 2021 second quarter is growth. We believe we have the building blocks in place for continued growth and we remain on track to achieve our near-term goal of establishing Twirla in the $4.1B U.S. hormonal contraceptive market," said chairman and CEO Al Altomari. "We have an approved product that is growing in all major prescription performance areas and we believe we are only scratching the surface as we unleash more direct-to-consumer advertising and further develop the channels that provide women access to Twirla."

ShowHide Related Items >><<
AGRX Agile Therapeutics
$1.12 /

-0.04 (-3.46%)

AGRX Agile Therapeutics
$1.12 /

-0.04 (-3.46%)

04/06/21 RBC Capital
Agile Therapeutics transferred with an Outperform at RBC Capital
12/08/20 H.C. Wainwright
Agile Therapeutics price target raised to $7 from $6 at H.C. Wainwright
09/22/20 H.C. Wainwright
H.C. Wainwright says Agile coverage, access for Twirla launch underappreciated
AGRX Agile Therapeutics
$1.12 /

-0.04 (-3.46%)

AGRX Agile Therapeutics
$1.12 /

-0.04 (-3.46%)

Over a quarter ago
Earnings
Agile Therapeutics reports Q1 EPS (20c), consensus (21c) » 16:26
05/04/21
05/04
16:26
05/04/21
16:26
AGRX

Agile Therapeutics

$1.72 /

-0.05 (-2.82%)

Reports Q1 revenue…

Reports Q1 revenue $116,000, consensus $160,000. "In December 2020, we began our initial commercial shipments of Twirla(R) to wholesalers, who have been working down their inventories during the first quarter of 2021. As wholesalers complete the inventory work-down, we expect product revenue from wholesalers will more closely reflect script demand growth for Twirla at the retail level. We are encouraged by recent trends, which we believe reflect our anticipated momentum and show steady, increasing demand for our product and a growing base of prescribers." said chairman and CEO, Al Altomari. "We continue to be optimistic about Twirla's trajectory and are encouraged by the response to our product, the first and only weekly contraceptive patch that delivers a low dose of estrogen."

ShowHide Related Items >><<
AGRX Agile Therapeutics
$1.72 /

-0.05 (-2.82%)

AGRX Agile Therapeutics
$1.72 /

-0.05 (-2.82%)

04/06/21 RBC Capital
Agile Therapeutics transferred with an Outperform at RBC Capital
12/08/20 H.C. Wainwright
Agile Therapeutics price target raised to $7 from $6 at H.C. Wainwright
09/22/20 H.C. Wainwright
H.C. Wainwright says Agile coverage, access for Twirla launch underappreciated
AGRX Agile Therapeutics
$1.72 /

-0.05 (-2.82%)

AGRX Agile Therapeutics
$1.72 /

-0.05 (-2.82%)

Hot Stocks
Agile Therapeutics presents Twirla data at ACOG Annual Meeting » 11:03
04/30/21
04/30
11:03
04/30/21
11:03
AGRX

Agile Therapeutics

$1.86 /

+0.045 (+2.48%)

Agile Therapeutics…

Agile Therapeutics announced that a post hoc analysis of the Phase 3 SECURE Trial evaluating the safety and efficacy of Twirla transdermal system in women with BMI less than 25 kg/m2 and women with BMI 25-30 kg/m2 will be presented at the American College of Obstetricians and Gynecologists Annual Clinical and Scientific Meeting from April 30 - May 2. Twirla was approved based on the Phase 3 SECURE Trial, a United States, multicenter, single-arm, open-label, 13-cycle trial that evaluated the efficacy, safety and tolerability of Twirla in 2,032 healthy women. Twirla is a combination of levonorgestrel and ethinyl estradiol indicated as a method of contraception for use in women of reproductive potential with a BMI less than 30 kg/m2 for whom a combined hormonal contraceptive is appropriate. The U.S. package insert also includes a Limitation of Use statement guiding prescribers to consider Twirla's reduced effectiveness in women with a BMI greater than or equal to 25 to less than 30 kg/m2 before prescribing. Twirla is contraindicated in women with a BMI greater than or equal to 30 kg/m2. This post hoc analysis of SECURE assessed the efficacy, safety and tolerability of Twirla in women with BMI less than 25 kg/m2 and BMI 25-30 kg/m2. When compared to women with BMI less than 25 kg/m2, Twirla demonstrated lower but acceptable efficacy while maintaining similar safety and tolerability in women with BMI 25-30 kg/m2. "The results of this post hoc analysis help to inform providers counseling women that fall within BMI 25-30 kg/m2 who may be considering a non-oral, noninvasive contraception option," said Anita Nelson, MD, Lead Author and Primary Investigator in the SECURE study. "These data support the safety and tolerability of Twirla in women within BMI 25-30 kg/m2 as well as those with BMI less than 25 kg/m2."

ShowHide Related Items >><<
AGRX Agile Therapeutics
$1.86 /

+0.045 (+2.48%)

AGRX Agile Therapeutics
$1.86 /

+0.045 (+2.48%)

04/06/21 RBC Capital
Agile Therapeutics transferred with an Outperform at RBC Capital
12/08/20 H.C. Wainwright
Agile Therapeutics price target raised to $7 from $6 at H.C. Wainwright
09/22/20 H.C. Wainwright
H.C. Wainwright says Agile coverage, access for Twirla launch underappreciated
AGRX Agile Therapeutics
$1.86 /

+0.045 (+2.48%)

AGRX Agile Therapeutics
$1.86 /

+0.045 (+2.48%)

Recommendations
Agile Therapeutics transferred with an Outperform at RBC Capital » 16:45
04/06/21
04/06
16:45
04/06/21
16:45
AGRX

Agile Therapeutics

$2.07 /

+0.01 (+0.49%)

RBC Capital transferred…

RBC Capital transferred coverage of Agile Therapeutics to analyst Daniel Busby, and kept an Outperform rating and $8 price target on the stock.

ShowHide Related Items >><<
AGRX Agile Therapeutics
$2.07 /

+0.01 (+0.49%)

AGRX Agile Therapeutics
$2.07 /

+0.01 (+0.49%)

12/08/20 H.C. Wainwright
Agile Therapeutics price target raised to $7 from $6 at H.C. Wainwright
09/22/20 H.C. Wainwright
H.C. Wainwright says Agile coverage, access for Twirla launch underappreciated
AGRX Agile Therapeutics
$2.07 /

+0.01 (+0.49%)

AGRX Agile Therapeutics
$2.07 /

+0.01 (+0.49%)

On The Fly
Fly Intel: Pre-market Movers » 08:56
03/24/21
03/24
08:56
03/24/21
08:56
INTC

Intel

$63.47 /

-2.19 (-3.34%)

, TSLA

Tesla

$662.17 /

-7.83 (-1.17%)

, HOFV

Hall of Fame Resort & Entertainment

$4.04 /

-1.22 (-23.19%)

, DLPN

Dolphin Entertainment

$18.20 /

+12.78 (+235.79%)

, AGRX

Agile Therapeutics

$1.89 /

-0.13 (-6.45%)

, IPHI

Inphi

$161.66 /

-3.58 (-2.17%)

, GIS

General Mills

$61.21 /

-0.29 (-0.47%)

, GME

GameStop

$181.00 /

-13.41 (-6.90%)

, EYES

Second Sight

$11.00 /

-1.65 (-13.04%)

, MP

MP Materials

$37.04 /

-8.165 (-18.06%)

, CASI

Casi Pharmaceuticals

$2.28 /

-0.11 (-4.60%)

, BTC

Bitcoin

$0.00 /

+ (+0.00%)

, BITCOIN

Bitcoin

$0.00 /

+ (+0.00%)

, MRVL

Marvell

$46.12 /

-1.56 (-3.27%)

Check out this morning's…

ShowHide Related Items >><<
TSLA Tesla
$662.17 /

-7.83 (-1.17%)

MRVL Marvell
$46.12 /

-1.56 (-3.27%)

MP MP Materials
$37.04 /

-8.165 (-18.06%)

IPHI Inphi
$161.66 /

-3.58 (-2.17%)

INTC Intel
$63.47 /

-2.19 (-3.34%)

HOFV Hall of Fame Resort & Entertainment
$4.04 /

-1.22 (-23.19%)

GME GameStop
$181.00 /

-13.41 (-6.90%)

GIS General Mills
$61.21 /

-0.29 (-0.47%)

EYES Second Sight
$11.00 /

-1.65 (-13.04%)

DLPN Dolphin Entertainment
$18.20 /

+12.78 (+235.79%)

CASI Casi Pharmaceuticals
$2.28 /

-0.11 (-4.60%)

BTC Bitcoin
$0.00 /

+ (+0.00%)

BITCOIN Bitcoin
$0.00 /

+ (+0.00%)

AGRX Agile Therapeutics
$1.89 /

-0.13 (-6.45%)

INTC Intel
$63.47 /

-2.19 (-3.34%)

03/24/21 Northland
Intel foundry initiative 'has a low probability of success,' says Northland
03/24/21 Rosenblatt
Intel adding new dimension of execution risk in foundry battle, says Rosenblatt
03/24/21 Evercore ISI
Intel price target raised to $75 from $68 at Evercore ISI
03/24/21 Needham
Intel price target raised to $74 from $70 at Needham
TSLA Tesla
$662.17 /

-7.83 (-1.17%)

03/24/21 Piper Sandler
Tesla selloffs on truck production delays likely, says Piper Sandler
03/24/21 Wedbush
Wedbush sees bitcoin accepted to buy a Tesla as 'major step' in crypto world
03/22/21 Deutsche Bank
Deutsche Bank raises Volkswagen price target to EUR 270, says 'all-in' on BEVs
03/22/21 Wedbush
Tesla puts strategic 'line in the sand' with China amid tensions, says Wedbush
HOFV Hall of Fame Resort & Entertainment
$4.04 /

-1.22 (-23.19%)

12/15/20 Maxim
Hall of Fame Resort & Entertainment initiated with a Buy at Maxim
DLPN Dolphin Entertainment
$18.20 /

+12.78 (+235.79%)

AGRX Agile Therapeutics
$1.89 /

-0.13 (-6.45%)

12/08/20 H.C. Wainwright
Agile Therapeutics price target raised to $7 from $6 at H.C. Wainwright
09/22/20 H.C. Wainwright
H.C. Wainwright says Agile coverage, access for Twirla launch underappreciated
IPHI Inphi
$161.66 /

-3.58 (-2.17%)

03/24/21 Stifel
Chinese approval for Inphi deal 'highly favorable' for Marvell, says Stifel
02/16/21 Needham
Inphi price target raised to $191 from $175 at Needham
02/09/21 Barclays
Inphi downgraded to Equal Weight on Marvell deal at Barclays
02/09/21 Barclays
Inphi downgraded to Equal Weight from Overweight at Barclays
GIS General Mills
$61.21 /

-0.29 (-0.47%)

01/19/21 JPMorgan
General Mills price target lowered to $55 from $62 at JPMorgan
01/12/21 Jefferies
General Mills price target lowered to $59 from $64 at Jefferies
09/25/20 Credit Suisse
General Mills upgraded to Outperform from Neutral at Credit Suisse
09/24/20 Citi
General Mills price target lowered to $64 from $70 at Citi
GME GameStop
$181.00 /

-13.41 (-6.90%)

03/24/21 BofA
GameStop Q4 EBITDA missed 'in a big way,' says BofA
03/24/21 Wedbush
Wedbush downgrades GameStop to sell with $29 price target
03/24/21 Wedbush
GameStop downgraded to Underperform from Neutral at Wedbush
03/19/21 BofA
GameStop-related stimulus conversations may not impact shares, says BofA
EYES Second Sight
$11.00 /

-1.65 (-13.04%)

04/01/20 H.C. Wainwright
Second Sight rating placed under review at H.C. Wainwright
MP MP Materials
$37.04 /

-8.165 (-18.06%)

03/10/21 Cowen
MP Materials initiated with an Outperform at Cowen
03/09/21 Deutsche Bank
MP Materials downgraded to Hold on valuation at Deutsche Bank
03/08/21 Deutsche Bank
MP Materials downgraded to Hold from Buy at Deutsche Bank
03/02/21
Fly Intel: Top five analyst initiations
CASI Casi Pharmaceuticals
$2.28 /

-0.11 (-4.60%)

10/23/20 Oppenheimer
Casi Pharmaceuticals initiated with an Outperform at Oppenheimer
BTC Bitcoin
$0.00 /

+ (+0.00%)

01/13/21 Standpoint Research
Bitcoin could hit $112,000 this year, says Standpoint Research
BITCOIN Bitcoin
$0.00 /

+ (+0.00%)

MRVL Marvell
$46.12 /

-1.56 (-3.27%)

03/12/21 Evercore ISI
Marvell added to Top Picks list, price target upped to $55 at Evercore ISI
03/08/21 BMO Capital
Marvell upgraded to Outperform from Market Perform at BMO Capital
03/04/21 Jefferies
Marvell long-term visibility better than previously thought, says Jefferies
TSLA Tesla
$662.17 /

-7.83 (-1.17%)

MRVL Marvell
$46.12 /

-1.56 (-3.27%)

MP MP Materials
$37.04 /

-8.165 (-18.06%)

IPHI Inphi
$161.66 /

-3.58 (-2.17%)

INTC Intel
$63.47 /

-2.19 (-3.34%)

GME GameStop
$181.00 /

-13.41 (-6.90%)

GIS General Mills
$61.21 /

-0.29 (-0.47%)

DLPN Dolphin Entertainment
$18.20 /

+12.78 (+235.79%)

CASI Casi Pharmaceuticals
$2.28 /

-0.11 (-4.60%)

AGRX Agile Therapeutics
$1.89 /

-0.13 (-6.45%)

  • 24
    Mar
  • 24
    Mar
  • 22
    Jul
  • 01
    May
TSLA Tesla
$662.17 /

-7.83 (-1.17%)

IPHI Inphi
$161.66 /

-3.58 (-2.17%)

INTC Intel
$63.47 /

-2.19 (-3.34%)

GME GameStop
$181.00 /

-13.41 (-6.90%)

GIS General Mills
$61.21 /

-0.29 (-0.47%)

BTC Bitcoin
$0.00 /

+ (+0.00%)

TSLA Tesla
$662.17 /

-7.83 (-1.17%)

MRVL Marvell
$46.12 /

-1.56 (-3.27%)

MP MP Materials
$37.04 /

-8.165 (-18.06%)

IPHI Inphi
$161.66 /

-3.58 (-2.17%)

INTC Intel
$63.47 /

-2.19 (-3.34%)

GME GameStop
$181.00 /

-13.41 (-6.90%)

GIS General Mills
$61.21 /

-0.29 (-0.47%)

EYES Second Sight
$11.00 /

-1.65 (-13.04%)

CASI Casi Pharmaceuticals
$2.28 /

-0.11 (-4.60%)

BTC Bitcoin
$0.00 /

+ (+0.00%)

BITCOIN Bitcoin
$0.00 /

+ (+0.00%)

TSLA Tesla
$662.17 /

-7.83 (-1.17%)

MRVL Marvell
$46.12 /

-1.56 (-3.27%)

MP MP Materials
$37.04 /

-8.165 (-18.06%)

INTC Intel
$63.47 /

-2.19 (-3.34%)

GME GameStop
$181.00 /

-13.41 (-6.90%)

GIS General Mills
$61.21 /

-0.29 (-0.47%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.